Taysha Gene Therapies (TSHA) Non-Current Debt (2021 - 2026)

Taysha Gene Therapies has reported Non-Current Debt for 6 years, with the latest figure at $49.0 million in Q1 2026.

• Quarterly Non-Current Debt rose 15.33% year-over-year to $49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.0 million (up 15.33% YoY) and the FY2025 annual result came in at $50.1 million, up 14.03% from the prior year.
• Non-Current Debt eased to $49.0 million in Q1 2026 per TSHA's latest filing, from $50.1 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $50.9 million in Q3 2025 and troughed at $37.4 million in Q1 2022.
• A 5-year average of $41.5 million and a median of $40.5 million in 2023 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 35.82% in 2022, then fell 1.35% in 2024.
• Over 5 years, Non-Current Debt stood at $38.0 million in 2022, then gained by 6.69% to $40.5 million in 2023, then gained by 8.48% to $43.9 million in 2024, then climbed by 14.03% to $50.1 million in 2025, then slipped by 2.29% to $49.0 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $49.0 million, $50.1 million, and $50.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.